deliv strong organ growth beat driven
ortho spine/neuro acceler top-line
consecut year continu expect anoth year
organ growth upsid driven continu strength
mako spine/neuro acceler remain overweight pt
beat right place report organ growth bp
estim reflect bp momentum acceler bp
momentum acceler ex medsurg beat driven ortho
organ vs mse momentum acceler bp driven knee
mako discuss spine/neuro organ growth bp
momentum acceler strongest quarter sinc driven stroke
spine improv turn organ medsurg organ growth
light estim toughest comp year see
intra-seg result skew posit investor typic prefer upsid
ortho spine neuro versu medsurg organ growth adj
sell day slight acceler vs seventh consecut year
acceler ceo kevin lobo margin line
estim improv bp y/i ep beat estim
mainli driven non-op vs mse top-line upsid vs mse
mako us knee neuro broke trend
mako system placement y/i strongest robot
quarter sinc launch materi ahead estim tka
util trend continu trend higher grow
bode well placement commentari suggest sale
strategy/pr chang although rental mix may modestli
increas japan instal base grew vs commentari
notabl bullish futur prospect market
driver quarter china tka approv expect later year
expand move forward longer
provid quarterli mako number like respons zimmer biomet
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
us knee organ growth vs mse strongest
absolut quarter nearli decad momentum acceler bp
strength attribut continu mako procedur growth y/i
sequenti demand print product cementless
mix continu grow vs prior commentari
suggest reach time note sinc launch mako
estim gain point share point higher
predict note robot shark ortho
neuro organ growth vs mse acceler bp
momentum basi note segment modestli lag peer
earlier part year due absenc larg bore aspir
sheath technic issu strength broad-bas geograph
across portfolio full portfolio expect end
see continu acceler segment next year discuss
get better wors organ growth guidanc
consist initi guidanc in-lin preview see
discuss previous continu expect upsid organ growth throughout
year beaten top end initi growth guidanc
averag bp past year outlin key sub-seg driver
spine pf growth miss compani origin msd plan
caution demonstr improv meet revis lsd
growth guidanc comp eas prior disrupt new
product launch build traction expect segment growth acceler
model spine growth drive bp corpor
neuro referenc outlook expect
neuro segment acceler base larg bore aspir
launch like sheath technic issu resolv earli
decemb continu traction ou product launch
model organ growth neuro bp corpor see
potenti upsid compani deliv averag
medsurg see key driver medsurg sever
acquisit turn organ drive bp corpor see
pipelin launch traction build year two manag
acknowledg anticip bed launch time non-
committ new lifepak launch previous expect
new disclosur state push see overli
surpris light recent lifepak recal see year
segment growth acceler see comp becom challeng
model growth note increment bp medsurg upsid
drive bp corpor
great margin debat ep growth acceler
second consecut year sinc institut floor see compani
averag midpoint ep guidanc
street modestli expect see
margin guidanc consist commentari follow wright
acquisit emb bp expans ex-wmgi dilut said
consid forecast dilut close
manag reiter expect achiev bp still
deliv posit margin improv eps-neutr impact wright
reiter model ep may prove conserv given
expect top-line upsid may impact time
wright close note stryker beaten top end initi ep guidanc
averag past year
zimmer biomet deck ortho market dynam
report ortho recon market estim ww recon market
grown strongest absolut quarter sinc
momentum basi impli bp momentum deceler howev
bp momentum improv basi impli bp
momentum acceler us knee model impli market growth
bp momentum acceler third consecut quarter
momentum improv notabl give market pressur earli
manag view market backdrop healthi time
note modest improv seen consist
expect price notabl better
could play role outlook manag forecast
materi chang continu view market stabl look
addit commentari zimmer biomet smith nephew report
come week ahead zimmer biomet result model us knee growth
underli bp momentum acceler remain comfort
impli flat share y/i q/q rosa model placement
vs see mako strength indic rosa traction lack
thereof given earli system launch
anoth strong finish remain overweight despit wright medic overhang
maintain favor view given see meaning
upsid consensu estim initi guidanc larg in-lin
expect consist prior practic expect
continu beat/rais throughout year driven top-line commentari
notabl upbeat date absenc clear driver
see reason expect point organ growth deceler impli
midpoint guidanc wright medic disrupt remain key variabl
discuss sever potenti pocket conservat manag deal
model see remain overweight increas price target
vs prior reflect increas peer multipl valuat
methodolog base price-to-earnings two-turn premium larg cap devic
deriv base case scenario multipl two-turn
premium larg cap peer see warrant given
durabl premium growth profil howev modestli larg cap
growth peer given leverag ep growth limit
organ growth acceler eighth consecut year
dilut wright medic acquisit mitig top-line upsid
synergi drive margin back bp annual share servic
opportun erp implement drive mid-teen earn growth
organ growth remain durabl driven mako penetr medsurg
durabl spine/neuro acceler margin expans like minim given
wright medic dilut ep growth like remain
organ growth slow point y/i driven downturn capit cycl spine
disrupt ortho competit margin progress remain mute driven
ineffici dilut
deliv consecut year
organ growth improv
potenti growth durabl
key theme driven mako medsurg
durabl acquisition-fuel growth
mako penetr still earli
knee hip provid ampl
runway mix benefit share gain
materi expans near-term
maintain commit ep
mako driven consecut year
market growth ww knee average
point market
medsurg growth durabl point
medsurg upsid drive bp growth
share servic opportun erp
implement provid opportun
margin expans bp margin expans
drive point ep growth
capit deploy buyback
risk achiev price
organ growth deceler y/i closer
wright medic dis-synergi dilut
greater forecast
competit environ ortho robot
million except ep
million
sale
sale
sale
sale
sale
sale
exhibit stryker chang model
neurotechnolog spine
good sold
good sold
current matur long-term debt
addit paid capit
chang oper asset liabil
oper activ
purchas market secur
proce sale market sec
purchas pp
invest activ
proce issuanc debt
repay debt
proce option excercis
repurchas common stock
financ activ
effect exchang rate
net chang
equival bop
equival eop
